? BMI View: We are broadly maintaining our forecasts for the Indonesian pharmaceutical market, the growth of which will be supported by the government’s quest for better healthcare provision and the industry’s desire to capitalise on these healthcare initiatives. However, higher inflation is expected to have a knock-on effect on pharmaceutical prices, which are already prohibitively high for large sections of the population, especially as most patients have to foot their own medical bills in full. ? Headline Expenditure Projections ? Pharmaceuticals: IDR58,553bn (US$6.25bn) in 2012 to IDR64,072bn (US$6.41bn) in 2013; +9.4% growth in local currency terms and +2.6% in …
Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=122221.
Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/indonesia-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.
No comments:
Post a Comment